Upgrade to SI Premium - Free Trial

Neurocrine Bio. (NBIX) PT Raised to $155 at Truist Securities

May 6, 2026 1:16 PM
Truist Securities analyst Danielle Brill raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $155.00 (from $140.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change